Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Blood-Brain Barrier (BBB) Shuttle and Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LRP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRP1 (Cluster II & Cluster IV) ECD-Fc Fusion Protein HEK293 expressed for native glycosylation. High purity (>95%), Endotoxin controlled (<1 EU/μg). Sequence Verified. Correct folding of ligand-binding clusters. |
View LRP1 Products |
| Gene Delivery | LRP1 Promise-ORF / Lentivirus Full-length ORF lentiviral particles for establishing stable LRP1-expressing cell lines for internalization and transcytosis assays. |
View LRP1 Products |
| Benchmark Ab | Anti-LRP1 Recombinant Antibody Recombinant positive control antibody for binding, internalization, and flow cytometry assays. |
View LRP1 Products |
| Validator | LRP1 siRNA Set For target knockdown verification and specificity validation in cell-based assays. |
View LRP1 Products |
| Related Target A | TFRC (Transferrin Receptor) Primary benchmark target for BBB-shuttle receptor-mediated transcytosis (RMT) comparisons. |
View TFRC Products |
| Related Target B | LDLR (Low-Density Lipoprotein Receptor) Subfamily member for off-target selectivity and cross-reactivity counter-screening. |
View LDLR Products |
| Related Target C | LRP2 (Megalin) Close homolog used for safety and specificity profiling to avoid nephrotoxicity. |
View LRP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Massive Target Size (~600 kDa) | Truncated, rationally designed Cluster II and Cluster IV ECD-Fc recombinant proteins preserving native ligand-binding conformations. |
| Subfamily Off-Target Cross-Reactivity | Homolog screening panel (LDLR, LRP2, LRP8) strictly verified by mass spectrometry and purity chromatography. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control constructs included. |
| False Positives in Endocytosis | Validated siRNA sets included for target-specific knockdown verification in cell-based assays. |
Live LRP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LRP1-targeted therapeutics is intensifying, with major players shifting focus from traditional oncology monoclonal antibodies to peptide/antibody-drug conjugates (ADCs) and blood-brain barrier (BBB) transcytosis shuttles. As first-generation brain-penetrant therapies reach the clinic, the next wave of R&D is targeting LRP1-mediated receptor-mediated transcytosis (RMT) to deliver biotherapeutics, oligonucleotides, and small molecules into the central nervous system (CNS).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| BBB Shuttle (Peptide/Ab) | Angiochem, Denali Therapeutics, Roche | Glioblastoma, Lysosomal Storage Diseases, Alzheimer's | Transcytosis & pH-dependent binding assays (Need high-purity Cluster II/IV proteins) |
| ADC / Conjugates | Academic/Biopharma Consortia | Advanced Solid Tumors, Glioblastoma | Internalization Assay (Need Lentivirus for stable cell line construction) |
| Monoclonal Antibodies | In-house discovery pipelines | Cardiovascular, Fibrosis, Oncology | Selectivity profiling (Need LRP1 vs LDLR/LRP2 counter-screening panels) |